摘要
目的研究美洛昔康联合小剂量秋水仙碱治疗痛风性关节炎的疗效及安全性,观察治疗前后炎性指标、红细胞沉降率变化。方法选取门诊收治的痛风性关节炎患者93例作为研究对象,采用隐匿数字随机法分为3组,美洛昔康组31例给予美洛昔康治疗,秋水仙碱组31例给予常规剂量秋水仙碱治疗,联合组采用美洛昔康联合小剂量秋水仙碱治疗,评价各组患者治疗前后症状改善情况及疗效,治疗前、后抽取空腹静脉血检测C反应蛋白(CRP)、红细胞沉降率(ESR)、尿酸水平,记录患者用药期间不良反应。结果联合组总有效率96.77%,高于秋水仙碱组的87.10%和美洛昔康组的70.97%,秋水仙碱组总有效率高于美洛昔康组,差异有统计学意义(P<0.05)。各组治疗后症状评分明显低于治疗前,差异有统计学意义(P<0.05)。联合组与秋水仙碱组治疗后症状评分低于美洛昔康组,症状缓解时间短于美洛昔康组,差异有统计学意义(P<0.05)。各组治疗后CRP、ESR水平均低于治疗前,差异有统计学意义(P<0.05)。联合组与秋水仙碱组治疗后CRP、ESR水平低于美洛昔康组,差异有统计学意义(P<0.05)。联合组与秋水仙碱组治疗后CRP、ESR水平差异无统计学意义(P>0.05)。各组治疗前、后血尿酸水平差异无统计学意义(P>0.05)。秋水仙碱组不良反应发生率为51.61%,高于美洛昔康组的16.13%与联合组的19.35%,差异有统计学意义(P<0.05)。联合组与秋水仙碱组不良反应发生率差异无统计学意义(P>0.05)。结论美洛昔康联合小剂量秋水仙碱治疗痛风性关节炎临床疗效显著,其能迅速改善患者关节疼痛症状,安全性高。
Objective To study the efficacy and safety of meloxicam combined with small dose colchicine in the treatment of gout arthritis,and to observe the changes of inflammatory indexes and erythrocyte sedimentation rate before and after treatment.Methods Ninety-three outpatients with gouty arthritis were included.Using hidden numbers method,they were randomly divided into three groups,meloxicam group,colchicine group and joint group;in which meloxicam,colchicine and combined meloxicam and colchicine treatment were given,respectively.The symptoms before and after treatment,and curative effect were compared.The c-reactive protein(CRP),erythrocyte sedimentation rate(ESR)and uric acid levels were recorded for compared.Adverse reaction was also recorded.Results The total effective rate of the joint group was 96.77%,which was higher than colchicine group(87.10%)and meloxicam group(70.97%).The total effective rate of the colchicine group was significantly higher than that of the meloxicam group(P<0.05).The symptom scores after treatment were significantly lower than before treatment(P<0.05).After treatment,symptom scores of the joint group and the colchicine group were significantly lower than those of the meloxicam group;and symptom remission time was significantly shorter than that of the meloxicam group(P<0.05).After treatment,CRP and ESR levels in each group were significantly lower than those before treatment(P<0.05).After treatment,CRP and ESR levels in joint group and colchicine group were significantly lower than those in meloxicam group(P<0.05).There was no significant difference in CRP and ESR levels between the joint group and colchicine group(P>0.05).There was no significant difference in serum uric acid level before and after treatment(P>0.05).The incidence of adverse reactions in the colchicine group was 51.61%,which was significantly higher than the meloxicam group(16.13%)and the combination group(19.35%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the joint group and colchicine group(P>0.05).Conclusion Meloxicam combined with colchicine in the treatment of gout arthritis has a significant clinical efficacy,which can rapidly improve the symptoms of joint pain with high safety.
作者
李东升
黎声飞
吕静
张永红
廖福苑
LI Dong-sheng;LI Sheng-fei;LYU Jing;ZHANG Yong-hong;LIAO Fu-yuan(The Department of Rheumatism Immunology,Ganzhou People's Hospital,Ganzhou 341000,Jiangxi,China)
出处
《广东医学》
CAS
2020年第14期1442-1445,共4页
Guangdong Medical Journal
基金
2018年度江西省卫生计生委科技计划项目(20187239)。
作者简介
通信作者:张永红,E-mail:lhs121@yeah.net。
